Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 1/20 | 0.53 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.49 |
| ▸ | SRC | P12931 | 8/20 | 0.49 |
| ▸ | EGFR | P00533 | 6/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 5/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 5/20 | 0.49 |
| ▸ | ABL1 | P00519 | 5/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.49 |
| ▸ | KIT | P10721 | 3/20 | 0.49 |
| ▸ | STK4 | Q13043 | 2/20 | 0.48 |
| ▸ | STK3 | Q13188 | 2/20 | 0.48 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.48 |
| ▸ | STK26 | Q9P289 | 2/20 | 0.48 |
| ▸ | STK24 | Q9Y6E0 | 2/20 | 0.48 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.48 |
| ▸ | STAT5A | P42229 | 1/20 | 0.48 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14824856 | 0.93 | PAK4 (0.51) | PAK4PKN1FGFR1SRCEGFR | |
| SCHEMBL15030204 | 0.92 | PKN1 (0.62) | PAK4PKN1FGFR1SRCEGFR | |
| SCHEMBL15035214 | 0.91 | PAK4 (0.54) | PAK4PKN1FGFR1SRCEGFR | |
| SCHEMBL14824728 | 0.91 | PKN1 (0.63) | PAK4PKN1FGFR1EGFRSTK4 | |
| SCHEMBL15035222 | 0.90 | WEE1 (0.54) | PAK4PKN1FGFR1SRCEGFR | |
| SCHEMBL14824636 | 0.89 | PKN1 (0.60) | PAK4PKN1FGFR1SRCEGFR | |
| SCHEMBL14824706 | 0.85 | PKN1 (0.60) | PAK4PKN1FGFR1SRCEGFR | |
| SCHEMBL14824855 | 0.85 | PKN1 (0.53) | PAK4PKN1FGFR1SRCEGFR | |
| SCHEMBL14824729 | 0.84 | PKN1 (0.61) | PAK4PKN1FGFR1EGFRSTK4 | |
| SCHEMBL14824680 | 0.84 | PKN1 (0.74) | PAK4PKN1FGFR1EGFRSTK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013086451-A2 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013043232-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PAK4 5/4885PKN1 326/4885FGFR1 1919/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | PAK4 5/4885PKN1 182/4885FGFR1 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.